Stakeholders told the U.S. FDA that the Commissioner’s National Priority Voucher (CNPV) pilot program, launched a year ago, has received mixed reviews as companies seek clearer expectations around the ultra-accelerated review pathway. At a June 4 listening session, concerns included how the program was introduced and how communications and review timelines align with sponsors’ needs, leaving the pilot’s future under question amid ongoing policy evolution.